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_____________________________________________________________________________________ 
ABSTRACT  
Stimuli such as inflammation or hypoxia induce
cytochrome P450 epoxygenase–mediated
production of arachidonic acid–derived
epoxyeicosatrienoic acids (EETs). EETs have
cardioprotective, vasodilatory, angiogenic, anti-
inflammatory, and analgesic effects, which are
diminished by EET hydrolysis yielding biologically
less active dihydroxyeicosatrienoic acids (DHETs).
Previous in vitro assays have suggested that
epoxide hydrolase 2 (EPHX2) is responsible for
nearly all EET hydrolysis; EPHX1, which exhibits
slow EET hydrolysis in vitro, is thought to
contribute only marginally to EET hydrolysis.
Using Ephx1-/-, Ephx2-/-, and Ephx1-/-/Ephx2-/- mice,
we show herein that EPHX1 significantly
contributes to EET hydrolysis in vivo. Disruption of
Ephx1 and/or Ephx2 genes did not induce
compensatory changes in expression of other Ephx
genes or CYP2 family epoxygenases. Plasma levels
of 8,9-, 11,12-, and 14,15-DHET were reduced by
38%, 44%, and 67% in Ephx2-/- mice compared
with wild-type (WT) mice, respectively; however,
plasma from Ephx1-/-/Ephx2-/- mice exhibited
significantly greater reduction (100%, 99%, and
96%) of those respective DHETs. Kinetic assays
and FRET experiments indicated that EPHX1 is a
slow EET scavenger, but hydrolyzes EETs in a
coupled reaction with cytochromes P450 to limit
basal EET levels. Moreover, we also found that
EPHX1 activities are biologically relevant, as
Ephx1-/-/Ephx2-/- hearts had significantly better
postischemic functional recovery (71%) than both
WT (31%) and Ephx2-/- (51%) hearts. These
findings indicate that Ephx1-/-/Ephx2-/- mice are a
valuable model for assessing EET-mediated
effects, uncover a new paradigm for EET
metabolism, and suggest that dual EPHX1 and
EPHX2 inhibition may represent a therapeutic
approach to manage human pathologies such as
myocardial infarction.
________________________________________ 
 
Cytochrome P450 epoxygenases can oxidize
arachidonic acid (AA) to form epoxyeicosatrienoic
acids (EETs) which have potent cardiovascular
effects. The biological effects of EETs are short-
lived in that they are rapidly hydrolyzed to less
active dihydroxyeicosatrienoic acids (DHETs) by
EPHX2, also known as soluble epoxide hydrolase
(sEH) (1). Indeed, Ephx2-/- mice have increased
EETs, decreased DHETs and improved outcomes
in vascular disease models, which provide the basis
for development of pharmacological EPHX2
inhibitors (1,2). EPHX2 inhibition increases EET
levels in vivo, and leads to cardioprotective,
vasodilatory, angiogenic, anti-inflammatory and
analgesic effects (1-3).
 http://www.jbc.org/cgi/doi/10.1074/jbc.RA117.000298The latest version is at 
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EPHX2 inhibitors, which have completed
phase I clinical trials, are under investigation for
treatment of neuropathic pain, and may hold
promise for treatment of other ailments. However,
genetic disruption of Ephx2 or EPHX2
pharmacological inhibition does not completely
abolish EET hydrolysis in vivo. Among the EETs, 
EPHX2 has the biggest effect on levels of its
preferred substrate, 14,15-EET, but has
diminishing effects on 11,12- and 8,9-EET which
are equal or more potent in cardiovascular
physiology (4-6). More complete or more broad
inhibition of fatty acid epoxide hydrolysis could
further potentiate the beneficial cardiovascular
effects of endogenously produced EETs.
Others have searched for additional enzymes
capable of hydrolyzing EETs (7). EPHX1, also
known as microsomal epoxide hydrolase (mEH), is
known to be capable of EET hydrolysis; however,
it is thought to play a minimal role. Compared to
EPHX2, EPHX1 is 10s- to 1000s-fold slower in in 
vitro EET hydrolysis assays, and is also less
abundant in vivo (1,7,8). In some tissues, such as
the brain, which has low EPHX2 expression,
EPHX1 is believed to be responsible for hydrolysis
of only a small fraction of its preferred substrate,
11,12-EET (1,8,9). Three other enzymes, EPHX3,
EPHX4, and PEG1/MEST, were identified based
on homology to the catalytic sites of EPHX1 and
EPHX2 (7). EPHX3 was reported to have high
catalytic efficiency towards fatty acid epoxides in 
vitro; however, Ephx3-/- mice exhibit no alterations
of fatty acid epoxide hydrolysis (10). EPHX4 and
PEG1/MEST have not yet been examined for fatty
acid epoxide hydrolase activity.
In this study, we demonstrate that EPHX1 is
responsible for a substantial proportion of EET
hydrolysis in vivo. Ephx1-/-Ephx2-/- have nearly
complete loss of DHET in plasma or tissue lysates.
Compared to Ephx1-/- and Ephx2-/- mice, Ephx1-/-
Ephx2-/- mice have significantly increased plasma
levels of nearly all fatty acid epoxide examined.
Kinetic and FRET analyses suggest that EPHX1
interacts directly with P450 epoxygenases and
likely participates in a coupled-reaction during
basal EET formation. These surprising findings
explain the large residual EET hydrolysis observed
in Ephx2-/- mice, reveal a mouse model with
improved potentiation of EET effects, present a
new paradigm for the role of EPHXs in EET
metabolism, and suggest that combined inhibition
of EPHX1 and EPHX2 represents a novel approach
to treatment of disorders such as ischemic heart
disease.
RESULTS  
In this study, we examined fatty acid epoxide
levels and metabolism in tissues and body fluids
from WT, Ephx1-/-, Ephx2-/- and Ephx1-/- Ephx2-/-
mice. Ephx1-/- and Ephx2-/- mice were previously
generated and maintained on a C57BL/6
background (11,12). In-crossing of
Ephx1+/- Ephx2+/- mice yielded pups with no overt
phenotypes; pups were born in normal Mendelian
ratios (Table S1), had similar body weights and
organ/body weight ratios (Table S2), and exhibited
no gross anatomical or histological abnormalities.
Mice showed expected alterations of gene
expression (Figure 1A-B). Ephx1-/- mice have been
reported to express low levels of a truncated, non-
coding, Ephx1 mRNA transcript (11). Ephx1
mRNA levels were reduced in Ephx1-/- and Ephx1-
/- Ephx2-/- mice relative to WT. Ephx2mRNA levels
were nearly absent in Ephx2-/- and Ephx1-/- Ephx2-/- 
mice. Likewise, EPHX1 protein was absent from
Ephx1-/- and Ephx1-/- Ephx2-/- mice, and EPHX2
protein was absent from Ephx2-/- and Ephx1-/-
Ephx2-/- mice. EPHX1 was detected in both the S-9
fraction, which contains both cytosol and
microsomes, and in microsomes. EPHX2 was
detected in both S-9 and microsomal fractions. This
is consistent with previous findings of nearly equal
distribution of EPHX2 between cytosolic and
microsomal fractions (13-15). We observed no
compensatory regulation of hepatic Ephx1, Ephx2, 
Ephx3 or Ephx4 mRNAs (Figure 1A, Figure S1). In
addition, hepatic expression of Cyp2c and Cyp2j
family members was also comparable across
genotypes. Similar Ephx1, Ephx2, Ephx3 and
Ephx4 expression profiles were observed in mouse
heart (Figure S2).
We quantified oxylipin levels in plasma from
WT, Ephx1-/-, Ephx2-/- and Ephx1-/-Ephx2-/- mice
using LC-MS/MS (Figure 2A-B, Table S3).
Disruption of Ephx1 alone did not alter plasma
14,15-EET, 11,12-EET, 8,9-EET or 5,6-EET levels
compared to WT, nor did it alter levels of epoxides
derived from linoleic acid (12,13-EpOME and
9,10-EpOME), docasahexaenoic acid
(19,20-EpDPE) or eicosapentaenoic acid (17,18-
EpETE). In contrast, Ephx1-/- plasma had
significantly lower levels of 8,9-DHET, 5,6-DHET,
19,20-DiHDPA and 17,18-DHET compared to
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WT. Plasma from Ephx2-/- mice had significantly
higher levels of 14,15-EET, 11,12-EET, 8,9-EET,
17,18-EpETE, 12,13-EpOME and 9,10-EpOME,
and significantly lower levels of 14,15-DHET,
11,12-DHET, 8,9-DHET and 12,13-DiHOME
compared to WT. Disruption of both Ephx1 and
Ephx2 more dramatically altered plasma oxylipin
levels. Compared to WT, Ephx1-/- Ephx2-/-mice had
significantly higher levels of every CYP-derived
epoxide measured except 5,6-EET. Importantly, in
Ephx1-/- Ephx2-/- mouse plasma, levels of all the
fatty acid diols were low or undetectable.
Moreover, compared to Ephx2-/- mice, plasma from
Ephx1-/- Ephx2-/- mice had significantly higher
levels of 11,12-EET, 17,18-EpETE, and 19,20-
EpDPE, and significantly lower levels of all diols
measured except 12,13-DiHOME. This data
suggest functional compensation of EPHX1 and
EPHX2 with regard to fatty acid epoxide hydrolysis
in vivo. Together, EPHX1 and EPHX2 account for
hydrolysis of the nearly all circulating epoxides
derived from arachidonic, linoleic,
eicosapentaenoic and docosahexaenoic acids.
Our in vivo data suggest a substantial role of
EPHX1 in hydrolysis of endogenous fatty acid
epoxides that was not predicted by prior in vitro
assays. In vitro kinetic assays, typically performed
at supraphysiologic (µM) substrate concentrations
(7,8), may underestimate the capacity for EPHX1
to hydrolyze fatty acid epoxides in vivo. Indeed,
intracellular EET levels are estimated to be in the
low nM range (16,17). To determine the relative
contribution of EPHX1 and EPHX2 to EET
hydrolysis at physiologically relevant
concentrations, liver lysates from all four genotypes
were incubated with exogenous 11,12-EET at 1-
1000 nM concentration (Figure 3). In this assay,
EPHX2 was the dominant hydrolase. Ephx1-/-
lysates showed no decrease in enzymatic activity
compared to WT, while Ephx2-/- lysates show
nearly complete reduction of hydrolysis (94-99%)
at all 11,12-EET concentrations. Ephx1-/- Ephx2-/-
lysates had a small additional decrease in 11,12-
EET hydrolysis compared to Ephx2-/- lysates. This
data suggest that EPHX1 is responsible for only a
small fraction (1-4%) of 11,12-EET hydrolysis in
the liver under these experimental conditions.
Our in vitro 11,12-EET hydrolysis assays do
not reflect the pattern observed in vivo where
EPHX1 contributes significantly to EET hydrolysis
in the absence of EPHX2. EPHX1 is localized to
the endoplasmic reticulum (ER) adjacent to the
P450s that generate EETs. While rarely studied for
its role in EET hydrolysis, EPHX1 metabolism of
xenobiotics has been extensively investigated (18).
Indeed, EPHX1 can bind to xenobiotic
metabolizing P450s, and this binding stimulates
EPHX1 activity in what might be a coupled reaction
(19-21). We hypothesized that EPHX1 may also
participate in a coupled reaction with P450s that
metabolize endogenous fatty acids. To test this, we
incubated WT liver microsomes, which contain
cytochromes P450, EPHX1 and EPHX2, with 10
µM arachidonic acid and increasing concentrations
of NADPH. High NADPH concentrations induced
rapid production of 11,12-EET (1900 pg/mg
protein/minute). Decreasing the concentration of
NADPH progressively slowed the rate of 11,12-
EET production to <100 pg/mg protein/min (Figure
4A and 4B). At the highest rate of EET production
(200 µM NADPH), disruption of EPHX1 did not
reduce hydrolysis, while disruption of EPHX2
reduced hydrolysis of 11,12-EET by 85%.
Disruption of both EPHX1 and EPHX2 abolished
11,12-EET hydrolysis. Thus, EPHX1 appears to be
responsible for 15% of EET hydrolysis under these
conditions. Importantly, the relative contribution of
EPHX1 to EET hydrolysis increased as the rate of
EET formation decreased. Thus, at 0.2 µM and 0.02
µMNADPH, EPHX1 was capable of 61% and 86%
of 11,12-EET hydrolysis, respectively. At the
lowest rate of EET production (no added NADPH),
EPHX1 was capable of hydrolyzing nearly all EETs
as they are formed. Formation and hydrolysis of
8,9- and 14,15-EET was similarly regulated
(Figures 4C-E). The contribution of EPHX1 and
EPHX2 to EET hydrolysis at low rates of EET
production closely resembles the pattern observed
in mouse plasma suggesting that in vivo production
of EETs by P450s occurs near the low end of
enzymatic capacity.
To support the presence of a coupled reaction
between P450s that metabolize endogenous fatty
acids and EPHX1, we examined physical
interactions between the enzymes using FRET
(Figure 5). EPHX1 was N-terminally labeled with
CFP, while CYP2C8 and CYP2C9 were labeled
with YFP. FACS-FRET measurements showed a
physical association between EPHX1 and both
CYP2C8 or CYP2C9. This association was as
robust as was observed with the positive control
[CYP2J5 and cytochrome P450 reductase
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(CYPOR)]. This direct interaction between the
enzymes suggests an active transfer of the EET
substrate that could have major implications on the
balance between the epoxide as the intermediate
and the diol as the final product of the enzymatic
cascade.
To further examine the relative roles of EPHX1
and EPHX2 in EET hydrolysis in an intact organ,
hearts were isolated and perfused in retrograde
fashion using the Langendorff method (4,22).
Perfusates from each genotype were collected
during the last 20 minutes of baseline and the first
20 minutes of reperfusion after global, no-flow
ischemia, and assayed for fatty acid epoxides and
diols by LC-MS/MS (Figure 6A, Table S4). Levels
of most of the fatty acid epoxides and diols in
Ephx1-/- and Ephx2-/- heart perfusates were similar
to those in WT at baseline and after reperfusion,
although Ephx1-/- heart perfusates had significantly
higher 19,20-EpDPE and significantly lower 19,20-
DiHDPA levels, and Ephx2-/- heart perfusates had
significantly higher 17,18-EpETE levels at
baseline. In contrast, Ephx1-/- Ephx2-/- heart
perfusates had significantly lower levels of 14,15-
DHET, 11,12-DHET, 19,20-DiHDPA and 17,18-
DHET than both WT or Ephx2-/- hearts at baseline
and during reperfusion. Of note, production of
11,12-EET + 11,12-DHET was approximately
800 pg/gram heart tissue/minute at baseline and
increased to 2200 pg/gram/min during reperfusion.
Likewise, production of 14,15-EET + 14,15-DHET
levels increased after reperfusion. Importantly,
EPHX1 contributed more to EET hydrolysis under
conditions where EET production occurred at lower
rates (i.e. at baseline).
Ephx2-/- hearts have improved functional
recovery after ischemia (4). We hypothesized, that
Ephx1-/- Ephx2-/- hearts, which have a more
profound reduction in EET hydrolysis to DHETs,
might have an additional improvement of
postischemic functional recovery. Baseline cardiac
parameters were similar in all four genotypes
(Supplemental Table 5). After 20 minutes of
ischemia, recovery of left ventricular developed
pressure (LVDP) at 40 minutes of reperfusion
(R40) in WT hearts was 31% (Figure 7). Disruption
of EPHX1 alone had no effect on LVDP recovery
(38%). Disruption of EPHX2 alone resulted in
significantly improved LVDP recovery (51%) as
we have previously reported (4). Remarkably,
LVDP recovery in Ephx1-/- Ephx2-/- hearts was
71%, which was significantly higher than both WT
and Ephx2-/- hearts. Consistent with this data, rate-
pressure product (RPP) was also significantly
higher in Ephx1-/- Ephx2-/- hearts compared to both
WT and Ephx2-/- hearts. Thus, reduced EET
hydrolysis in Ephx1-/- Ephx2-/- hearts has important
functional consequences.
Taken together, our data suggest a new
paradigm for EET hydrolysis by epoxide
hydrolases (Figure 8). When EET formation rates
are low (e.g., under basal conditions), EPHX1 can
hydrolyze most of the EETs as they are formed
through a coupled reaction with P450 enzymes;
EPHX2 contributes minimally. However, when
EET production rates are high (e.g., during
postischemic reperfusion), EPHX1 capacity is
overwhelmed and EPHX2 contributes significantly
to EET hydrolysis. Thus, EPHX2 is an excellent
EET scavenger; it readily clears EETs from the
cytosol. By contrast, EPHX1 is a slow EET
scavenger, but it contributes significantly to EET
hydrolysis under basal conditions. The role of
EPHX1 with regard to EET hydrolysis is unmasked
in the absence of EPHX2.
DISCUSSION 
In summary, this manuscript contains several
important and novel findings regarding the
functional role of epoxide hydrolases: 1) disruption
of both EPHX1 and EPHX2 almost completely
abolishes EET hydrolysis in mouse plasma; 2) in 
vitro kinetic assays demonstrate that, relative to
EPHX2, EPHX1 is a poor EET scavenge; 3)
EPHX1 plays a prominent role in EET hydrolysis
when EET formation rates are low; 4) disruption of
both EPHX1 and EPHX2 suppresses EET
hydrolysis in mouse heart; and 5) Ephx1-/- Ephx2-/-
hearts have significantly improved recovery of
cardiac function after ischemia compared to both
WT or Ephx2-/- hearts. Together, these findings
dramatically alter our understanding of fatty acid
epoxide hydrolysis and may have many important
clinical and therapeutic implications.
The contribution of EPHX1 to EET hydrolysis
is surprising in several respects. Our findings are in
stark contrast to prior studies which suggest that
EPHX1 is too slow to contribute significantly to
EET hydrolysis and may only contribute to
hydrolysis of a selective subset of fatty acid
epoxides (7,8). In vitro, EPHX2 shows higher
catalytic activity than EPHX1 for most epoxides.
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These published in vitro studies poorly reflect the
fact that EPHX1 significantly contributes to
hydrolysis of a broad spectrum of fatty acid
epoxides in vivo. EPHX2 likely maintains higher
catalytic capability in vivo relative to EPHX1.
Morriseau and co-workers note that tissue
concentrations of EPHX2 are 3nM to 400 nM,
while EET concentrations are in the low nM range.
They conclude that, for EPHX2, substrate
accessibility, not hydrolase activity, is the limiting
factor for the conversion of epoxy fatty acids (23).
While EPHX1 may have lower catalytic capability
than EPHX2, it likely has increased accessibility to
epoxy fatty acids. For most epoxides, the role of
EPHX1 only becomes apparent in Ephx1-/- Ephx2-/-
mice or tissues. With the exception of 12,13-
EpOME, EPHX1 significantly regulates every fatty
acid epoxide examined. Ephx1-/- Ephx2-/- plasma
contain low levels of both DiHOMEs. These data
may suggest a minor role for additional hydrolases
such EPHX3, which shows high catalytical activity
toward 9,10-EpOME (7).
EPHX1 appears to act primarily as a ‘first-pass’
hydrolase for fatty acid epoxides. It has little
capacity to scavenge EETs out of the cytosol.
Under normal physiologic conditions, our data
suggests that P450s generate EETs at a fraction of
their maximal capacity (~5%). The reason that
EPHX1 can significantly contribute to EET
hydrolysis in vivo is that majority of epoxy fatty
acids formed occurs at low basal levels in most
tissues, most of the time. Ischemia and other stimuli
such as inflammation activate cytosolic
phospholipase A2 which releases AA from
membrane phospholipid stores. The free AA can
then be rapidly metabolized by P450s to EETs. At
these higher rates of EET formation, the limited
capacity of EPHX1 is surpassed and significant
‘EET-signal’ is produced; EPHX2 plays a
predominate role under these stimulated conditions.
We propose that P450 epoxygenases and
EPHX1 biosynthesize and hydrolyze EETs in a
manner analogous to xenobiotics (24,25). For
xenobiotic metabolism, a coupled reaction prevents
the release of highly reactive epoxide intermediates
into membranes or cytosol. One alternative is that
P450-derived epoxides may not be immediately
hydrolyzed but rather remain associated with the
ER membrane similar to other lipophilic molecules
(26,27). EPHX1, tethered to the ER, may
effectively scavenge these EETs. It is possible that
EPHX2, which is known to be ‘trapped’ or bound
to microsomes (Figure 1) (14,28), might also
hydrolyze EETs off membranes in a similar
fashion.
In vitro kinetic assays using recombinant
proteins dramatically underestimated the potential
of EPHX1 as a relevant hydrolase for a wide panel
of fatty acid epoxides. The cytoplasmic enzyme
EPHX2 excels at high throughput metabolism of
exogenous EETs in solution. It should not be
surprising that EPHX1 performs slowly under
conditions that poorly reflect its normal cellular
environment. EPHX1 may have much higher
hydrolase activity in vivo for several reasons: 1)
EPHX1/P450 binding might stimulate hydrolase
activity (19); 2) EPHX1 might benefit from direct
substrate handoff in a coupled reaction with P450s
(24); 3) EPHX1 might have higher activity when
embedded in ER membranes; and 4) EPHX1 may
have an advantage in scavenging free EETs that
remain associated with ER membranes. Previous
findings obtained in highly dilute solublized
solutions may not translate well to the complex,
concentrated, membrane-containing environments
found in vivo. Our findings represent another
cautionary tale of the perils of estimating
metabolism of lipophilic molecules by membrane-
bound enzymes that have been taken out of their
native environment (26,27,29).
A coupled reaction between P450s and EPHX1
suggests tight regulation of basal EET
concentrations; however, this reaction may also
suggest the possibility of a concerted mechanism
for producing bioactive diols. While fatty acid
epoxides are commonly thought of as the more
active oxylipin, fatty acid diols do retain some
selective bioactivity. For example, 11,12-DHET
lacks anti-inflammatory or mitogenic effects, but is
vasodilatory in some vascular beds (3,5,6) and
attenuates cAMP production in forskolin-
stimulated cells (30). The AA-derived diols have
little effect on angiogenesis; however, the DHA-
derived diol, 19,20-DiHDPA is reported to promote
retinal angiogenesis (31-33). Thus, EPHX1 may
play a role in both limiting basal epoxide signaling
and promoting physiological responses through
production of bioactive diols.
Our data in the various Ephx-/- mice and tissues
shed light on regulation of EETs in cells that lack
either EPHX1 and EPHX2. EPHX1 can hydrolyze
a significant proportion of EETs in EPHX2-
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deficient cells; likewise, EPHX2 can hydrolyze a
significant proportion of EETs in cells with low
EPHX1 expression. Ephx2 is abundantly expressed
in several tissues including liver, ovary, kidney and
intestinal tissues, but is expressed at much lower
levels in the lung, brain, skin and testes (Figure
S3A). In contrast, Ephx1 is abundant in liver, lung,
ovary and testes, but is expressed at lower levels in
other tissues including the heart (Figure S3B).
Moreover, within a given tissue, expression of
EPHX1 and EPHX2 varies by cell type. For
example, in the heart, EPHX2 is abundant in
cardiomyocytes and endothelial cells, but
expressed at low levels in smooth muscle cells and
fibroblasts; in the liver, EPHX2 is abundant in
hepatocytes, but expressed at low levels in
endothelial cells (Figure S3C). It is remarkable that
despite its low level of expression in heart, EPHX1
contributes significantly to EET hydrolysis in this
tissue under basal conditions. EPHX1 may also
play a more prominent role in hydrolysis of fatty
acid epoxides in tissues or cells where EPHX2
expression is low or absent. EPHX2 also contains a
functional lipid phosphatase domain (34). While
endogenous substrates for this domain have not
been identified, its presence suggests that EPHX2
may have important physiological roles aside from
fatty acid epoxide hydrolysis.
There is substantial variation in the human
EPHX1 gene. There are over 140 single nucleotide
polymorphisms (SNPs) listed in the National
Cancer Institute dbSNP database
(https://www.ncbi.nlm.nih.gov/snp/). The most
frequently studied SNPs are Y113H (rs1051740)
and H139R (rs2234922), both of which are believed
to reduce EPHX1 activity (18). EPHX1 has been
widely studied for its role in bioactivation or
detoxification of carcinogens (35) and associations
of EPHX1 polymorphisms with cancer have been
found (18). EETs are mitogenic, anti-apoptotic and
pro-angiogenic (3) and promote tumor growth and
metastasis (32). Thus, EPHX1, via its regulation of
EET-mediated effects, may also modulate tumor
growth independent of its role in carcinogen
metabolism. While EPHX1 polymorphisms have
not yet been examined with respect to
cardiovascular disease outcomes, our findings
suggest a role for EPHX1 in diseases such as
atherosclerosis, sepsis, stroke and MI, independent
of their role in xenobiotic metabolism.
Our findings may also have important clinical
implications. Preclinical studies have demonstrated
that EPHX2 disruption or inhibition improves
postischemic cardiac functional recovery and
reduces MI (4,36-38). EPHX2 inhibitors, which
have completed phase I clinical trials (39), have
been proposed as treatments for patients suffering
MI (40,41). Our data suggest that dual inhibition of
EPHX1 and EPHX2 might offer additional benefit
to MI patients. EPHX1 appears to play a
particularly important role in omega-3 fatty acid
epoxide hydrolysis. While less well studied,
EpETEs and EpDPEs appear to have potent EET-
like properties (42). In addition, 17,18-EpETE and
19,20-EpDPE have potent antiarrhythmic effects in
the heart (43). Given the important role of EPHX1
in xenobiotic metabolism, long term use of EPHX1
inhibitors may be unwise; however, our data
suggests a possible benefit for dual inhibition of
EPHX1 and EPHX2 in acute treatment of cardiac
arrhythmia and sudden cardiac death.
Our data suggest a new paradigm for hydrolysis
of EETs; however, several important questions
remain. While EPHX1 and EPHX2 together
account for nearly all EET hydrolysis observed in
mouse plasma in vivo, Ephx1-/- Ephx2-/- mice
exhibit appreciable hydrolysis of 9,10- and 11,12-
EpOME (~20% that of WT mice). Moreover,
Ephx1-/- Ephx2-/- hearts produce significant amount
of DHETs during reperfusion. EPHX3 has been
shown to have high catalytic activity against EETs
and 9,10-EpOME in vitro (7); however, Ephx3-/-
mice exhibit normal fatty acid epoxide hydrolase
activity in multiple tissues, both in vitro and in vivo
(10). Whether the residual fatty acid epoxide
hydrolysis in Ephx1-/- Ephx2-/- mice is due to
EPHX3 remains unknown. In addition, while
Ephx1-/- Ephx2-/- mice have dramatically reduced
plasma levels of fatty acid diols, this does not
always correspond to increases in plasma levels of
the corresponding fatty acid epoxides. In this
regard, EETs may be shunted toward other
metabolic pathways in cells lacking EPHX2
activity. Inhibition of EPHX2 increases EET
esterification into plasma membranes and
formation of chain-shortened epoxides (44-46).
These chain-shortened epoxides can maintain
potent biological activities (47), which may explain
why Ephx2-/- and Ephx1-/- Ephx2-/- hearts show
improved functional recovery despite minimal
increases in EETs.
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In conclusion, our findings represent a
significant advance in the eicosanoid field. The
discovery that EPHX1 contributes significantly to
EET hydrolysis in vivo explains the enigmatic
residual hydrolysis observed after EPHX2 genetic
disruption or pharmacological inhibition, and
represents a new paradigm for the role of EPHXs in
EET metabolism. The findings suggest new
avenues of research regarding the role of EPHX1
polymorphisms in human disease, and offers a
novel therapeutic target for the treatment of
ischemic heart disease.
EXPERIMENTAL PROCEDURES: 
Animals–Mice with constitutive global
disruption of Ephx1 (Ephx1-/-) and Ephx2 (Ephx2-/-)
were generated as previously described (11,12) and
generously provided by Dr. Frank Gonzalez (NCI).
Mice were back-crossed for more than 10
generations onto a pure C57BL/6 background.
Ephx1+/- Ephx2+/- mice were in-crossed to produce 
Ephx1+/+ Ephx2+/+ (WT), Ephx1-/- Ephx2+/+ (Ephx1-
/-), Ephx1+/+ Ephx2-/- (Ephx2-/-), and Ephx1-/- Ephx2-
/- mice for study. Relatively equal proportions of
male and female mice, aged 10-20 weeks, were
used in each study. Mice were maintained in cages
with a 12:12 hour light-dark cycle and free access
to NIH 31 chow (Envigo, Madison, WI) and water.
All procedures were in accordance with the NIH 
Guide for the Care and Use of Laboratory Animals,
and were approved by the NIEHS Animal Care and
Use Committee.
Langendorff Isolated Perfusion–Mice were
anesthetized with pentobarbital, hearts were
removed, cannulated, and perfused in the
Langendorff mode as previously described (4,22).
Hearts were perfused with modified Krebs–
Henseleit buffer (120 mM NaCl, 25 mM NaHCO3,
4.7 mM KCl, 1.2 mM KH2PO4, 1.20 mM MgSO4,
11 mM glucose, and 1.8 mM CaCl2) bubbled with
95% air and 5% CO2. A water-filled balloon
connected to a pressure transducer was inserted into
the left ventricle to monitor cardiac function. Hearts
were equilibrated for 40 minutes and then subjected
to 20 minutes of global, no-flow ischemia, followed
by 40 minutes of reperfusion. Recovery of
contractile function was measured as left
ventricular developed pressure (LVDP) at the end
of reperfusion expressed as a percentage of
preischemic LVDP. Rate pressure product (RPP)
was calculated as LVDP x heart rate. N=8-10/group
with roughly equal proportions of males and
females in each genotype group. In separate
experiments to collect heart perfusates for LC-
MS/MS analysis, hearts were cannulated and
perfused as above but without balloon insertion.
Heart perfusates were collected during the last 20
minutes of equilibration (Baseline) and during the
first 20 minutes of reperfusion into 50 ml conical
tubes containing 5 µL of 10 mM trans-4-[4-(3-
adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic
acid (t-AUCB; kindly provided by Bruce
Hammock, UC Davis) on dry ice and stored
at -80oC prior to extraction and analysis. N=6-
7/group with roughly equal proportion of males and
females in each genotype group.
Cell Fractionation and Protein 
Immunoblotting–All chemicals were from Sigma
(Saint Louis, MO) unless otherwise noted. Cell
fractionation was performed similarly to previously
published methods (48). 100 mg liver tissue was
added to 900 µl ice cold lysis buffer (0.25 M
Sucrose, 10 mM Tris (pH 7.5), 0.2 µg/ml leupeptin,
0.04 U/ml aprotinin, 0.25 µM PMSF) and
homogenized using a Tissuelyzer II (single
stainless steel beads, 4oC, 10 minutes at 30 Hz). The
homogenate was centrifuged 3 times at 9,000 x g
for 10 minutes. The 9,000 x g supernatant, which
contained both cytosol and microsomes, was
considered the S9 fraction. The 9,000 g supernatant
was centrifuged at 100,000 x g for 90 minutes,
washed with 0.15 M KCl, and centrifuged again at
100,000 x g. Microsomal pellets were resuspended
in 50 mM Tris (pH 7.5) containing 1 mM DTT, 1
mM EDTA and 20% glycerol. S9 fraction and
microsomal protein concentrations were
determined by BCA Assay (Biorad).
20 µg of microsomes or S9 fractions were
separated by 10% SDS-PAGE and transferred to
nitrocellulose. Membranes were blocked overnight
at 4oC in PBS containing 0.1% Tween 20 and 5%
nonfat milk (PBS-T/NFM). Membranes were
probed with antibodies to EPHX1 (sc-135984 at
1:200; Santa Cruz Biotechnology, Santa Cruz, CA)
or EPHX2 (sc-25797 at 1:1000; Santa Cruz
Biotechnology) in PBS-T/NFM for 2 hours at room
temperature. Blots were stripped and re-probed
with β-actin (clone AC-74 at 1:5000; Sigma).
Staining was detected using HRP-conjugated
secondary antibodies from Calbiochem (1:5000
dilution) and enhanced chemiluminescence.
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mRNA Analysis–mRNAwas isolated from liver
and heart tissues using RNeasy Mini Kits from
Qiagen (Valencia, CA) and converted to cDNA
using High Capacity cDNA Reverse Transcription
Kit from Life Technologies (Carlsbad, CA). Ephx1
(#Mm00468752_m1), Ephx2
(#Mm00514706_m1), Ephx4 (#Mm01203346_m1)
andGapdh (Mm99999915_g1) were detected using
TaqMan probes according to manufacturer’s
instructions. Ephx3, Cyp2c and Cyp2j expression
was detected by SYBR Green using established
methods (7,49) N=5-8/group with roughly equal
proportions of male and female livers and hearts.
EET hydrolysis assay–200 µg liver lysates were
mixed with ice cold solutions containing 0, 1, 10,
100, or 1000 nM 11,12-EET (Cayman Chemical,
Detroit, MI) in a total of 100 l PBS containing
0.1% BSA. Samples were incubated at 37oC for 5
minutes before reactions were stopped by the
addition of 1 ml ice cold PBS. 10 µl of internal
standard [30 ng each of PGE2-d4, 11,12-EET-d11,
and 11,12-DHET-d11 (Cayman)] was then added to
each sample and lipids were extracted with 2 ml
ethyl acetate, placed into tubes containing 6 µl of
30% glycerol in methanol, dried under vacuum
centrifugation, covered with argon gas, and stored
at -80oC N=4/group, liver lysates were prepared
from 2 males and 2 females for each genotype.
AA metabolism assay–50 µg liver microsomes
were added to a reaction buffer (50 mMTris-Cl (pH
7.4), 150 mM KCl, 10 mM MgCl2) containing 10
M arachidonic acid (Cayman Chemical) and 0,
0.02, 0.2, 2, 20, or 200 µM NADPH (Sigma).
Samples were incubated for 10 minutes at 37oC. A
control reaction (10 M arachidonic acid, 0 µM
NADPH) was kept on ice for 10 mins. Rates of lipid
formation were corrected for metabolites found in
this control reaction. Reactions were stopped by the
addition of 2 ml ethyl acetate and lipids were
extracted as described above. N=4, microsomes
were prepared from livers of 2 male and 2 female
mice of each genotype.
Mouse plasma–200 µl mouse plasma was
spiked with internal standard, mixed with 1 vol of
0.1% acetic acid in 5% methanol, and extracted
with 3 ml ethyl acetate. Ethyl acetate was passed
through Maestro A columns (Tecan, Mannedorf,
Switzerland) under gravity flow into glass tubes
containing 6 µL of 30% glycerol in methanol.
Columns were washed with 1 ml acetonitrile
(Sigma) and samples were dried and stored as
above.
Cardiac Perfusates–Samples were spiked with
internal standards, mixed with 0.1 vol of 1% acetic
acid in 50% methanol, and extracted by serial
passage through Oasis HLB C18 3 mL columns
(Waters, Milford, MA, USA). Columns were
washed twice with 3 ml 0.1% acetic acid in 5%
methanol and eluted with methanol into glass tubes
containing 6 µL of 30% glycerol in methanol.
Samples were dried and stored as above.
Liquid Chromatography Tandem Mass 
Spectroscopy–All samples were reconstituted in 50
µL of 30% ethanol. Online liquid chromatography
was performed with an Agilent 1200 Series
capillary HPLC (Agilent Technologies, Santa
Clara, CA, USA). Separations were achieved using
a Halo C18 column (2.7 um, 100 x 2.1 mm; MAC-
MOD Analytical, Chadds Ford, PA), which was
held at 50°C. Mobile phase A was 85:15:0.1 water:
acetonitrile: acetic acid. Mobile phase B was
70:30:0.1 acetonitrile: methanol: acetic acid. Flow
rate was 400 µL/min; Gradient elution was used.
Mobile phase percentage B and flow rate were
varied as follows: 20% B at 0 min, ramp from 0 to
5 min to 40% B, ramp from 5 to 7 min to 55% B,
ramp from 7 to 13 min to 64% B. From 13 to 19
min the column was flushed with 100% B at a flow
rate of 550 µL/min. Samples were solvated in 50 µl
of 30% ethanol. The injection volume was 10 µL.
Samples were analyzed in duplicate. Analyses were
performed on an MDS Sciex API 3000 equipped
with a TurboIonSpray source (Applied
Biosystems). Turbo desolvation gas was heated to
425°C at a flow rate of 6 L/min. Negative ion
electrospray ionization tandem mass spectrometry
with multiple reaction monitoring was used for
detection. Analyte quantification was performed
using Analyst 1.5.1 software (AB Sciex, Ontario,
Canada). Relative response ratios of analytes and
respective internal standards were compared to a
standard curve of response ratios for each analyte.
Lipid standards were stored in 100% ethanol under
argon and used within 1 year of purchase from
Cayman Chemical (Detroit, MI).
FRET-based FACS analysis of CYP-EPHX1 
interaction–CYP and EPHX1 proteins were N-
terminally fused to YFP and CFP, respectively. The
resulting ER luminal localization of these
fluorescent proteins results in a positive FRET
signal if the two attached proteins interact on the
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other side of the membrane. Details and validation
of this procedure, called FRET analysis of
membrane protein interaction in the endoplasmic
reticulum (FAMPIR) have previously been
described (50). The negative control pair was an ER
membrane anchored YFP with CYP2J5-CFP. The
positive control pair was CYP2J5-YFP with
cytochrome P450 reductase (CYPOR)-CFP. In
brief, transient transfection of HEK-293 cells with
a vector affording the expression of the two above
fusion proteins was carried out using jetPEI®
(Polyplus-Transfection, Illkirch, France),
according to the suppliers instructions. After 48 h,
cells were trypsinized and subjected to FACS
analyses on a LSR II Fortessa (BD Biosciences,
Franklin Lakes, NJ), using the sensitized emission
method. The following filter settings were
employed: YFP channel (488 nm, 530/30 filter, 505
LP); CFP channel (405 nm, 450/50 filter); FRET
channel (405 nm 525/50 filter, 505 LP). Five x 104
cells were analyzed per sample. Bleed-through of
the CFP and YFP signals into the FRET channel
was compensated for by adjusting the respective
recording parameters, using cells expressing only
CFP or YFP chimeras. During analysis, the FRET
intensity in the subpopulation displaying significant
YFP and CFP expression was recorded and plotted
against the intensity of the CFP fluorescence.
Individual replicates were produced by separate
transfection and FACS analyses for each data point.
Typically, the different combinations of potential
interaction partners were run in parallel.
Statistical Analyses–Analysis of significance
was determined by one-way ANOVA followed by
post hoc t-tests using GraphPad Prism and
Microsoft Excel software. For plasma analytes and
biochemical assays, the only tests considered were
as follows: WT vs. Ephx1-/-, WT vs. Ephx2-/-, WT
vs. Ephx1-/- Ephx2-/- and Ephx2-/- vs. Ephx1-/- Ephx2-
/- mice. For cardiac perfusates, in addition to these
comparisons, we conducted paired Student’s t-tests
to assess changes between baseline and
postischemic analyte levels. P-values less than 0.05
were considered significant.
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FIGURE LEGENDS 
 
FIGURE 1. Hepatic epoxide hydrolase expression in WT and Ephx-deficient mice. A) Ephx1 and 
Ephx2mRNA levels in livers fromWT, Ephx1-/-, Ephx2-/- and Ephx1-/- Ephx2-/-mice relative toGapdh; N=4
mice per genotype group. B) Expression of EPHX1, EPHX2 and β-actin proteins in liver S9 and microsomal
fractions from WT, Ephx1-/-, Ephx2-/- and Ephx1-/- Ephx2-/- mice.
FIGURE 2. Plasma oxylipin levels in WT or Ephx-deficient mice. A) Plasma levels of AA-derived
epoxides and diols in WT, Ephx1-/-, Ephx2-/- and Ephx1-/- Ephx2-/- mice. B) Plasma levels of
docasahexaenoic-, eicosapentaenoic- and linoleic acid-derived epoxides and diols in WT, Ephx1-/-, Ephx2-
/- and Ephx1-/- Ephx2-/- mice; N=9-11/group. *p<0.05 vs. WT; # p<0.05 vs. Ephx2-/-.
FIGURE 3. Relative contribution of EPHX1 and EPHX2 to EET hydrolysis in liver S9 fractions. A)
Metabolism of 11,12-EET (1-1000 nM) by liver lysates from WT, Ephx1-/-, Ephx2-/- and Ephx1-/- Ephx2-/-
mice. N=4/group. *p<0.05 vs. WT; # p<0.05 vs. Ephx2-/-.
FIGURE 4. Relative contribution of EPHX1 and EPHX2 to hydrolysis during EET formation in liver 
microsomes. Microsomes made from livers of WT, Ephx1-/-, Ephx2-/- and Ephx1-/- Ephx2-/- mice were
incubated with 10 M arachidonic acid in the presence/absence of increasing concentration of NADPH.
Relative formation of 11,12-DHET (A), 11,12-EET (B), 14,15-DHET (C), 14,15-EET (D), 8,9-DHET (E),
and 8,9-EET (F) at 0-200 M NADPH are shown as a percent of WT (A, C, E) or Ephx1-/- Ephx2-/- (B, D,
F). Formation rates at each NADPH concentration are shown above each group in pg/mg protein/minute.
N=4 per group, * p<0.05 vs. WT; # p<0.05 vs. Ephx2-/-.
FIGURE 5. Direct interaction between CYP2C epoxygenases and EPHX1. A) Schematic of membrane
topology of the YFP-CYP and the CFP-EPHX1 fusion proteins used for the FRET analysis. Intracellular
co-localization of the above fusion proteins in HEK-293 cells (1 = YFP (red), 2 = CFP (green), 3 = co-
localization (yellow); scale bar = 10 µm). B) Representative FACS analyses of FRET-positive cells for the
negative control, CYP2C8-EPHX1, and CYP2C9-EPHX1 interactions. FRET signal intensity (abscissa) is
plotted against CFP signal intensity (ordinate). Gated areas contain FRET positive cells. C) Percentage of
FRET-positive cells calculated form 3-5 independent replicate experiments except n=1 for the positive
control (CYP2J5- cytochrome P450 reductase (CYPOR)). * p < 0.0001 vs. negative control (CYP2J5-ER-
membrane-anchor)
FIGURE 6. Role of EPHX1 and EPHX2 in regulating heart oxylipin levels. Oxylipin levels in cardiac
perfusates from WT, Ephx1-/-, Ephx2-/-, and Ephx1-/- Ephx2-/- hearts expressed as pg/gram heart
tissue/minute. N=6-7 per genotype group, *p<0.05 vs. WT; #p<0.05 vs. Ephx2-/-.
FIGURE 7. Role of EPHX1 and EPHX2 in in postischemic recovery of heart function. A) Recovery
of Left Ventricular Developed Pressure (LVDP) and (B) Rate Pressure Product (RPP) at 40 minutes of
postischemic reperfusion (R40) as percent of Baseline in WT, Ephx1-/-, Ephx2-/- and Ephx1-/- Ephx2-/- mice.
N=8-10 per genotype group, *p<0.05 vs. WT; #p<0.05 vs. Ephx2-/-.
FIGURE 8. New paradigm for hydrolysis of EETs. Cytochrome P450 epoxygenases are localized to the
cytoplasmic face of the endoplasmic reticulum adjacent to EPHX1. EPHX2 is predominantly cytoplasmic.
When EET formation occurs at low rates (e.g., basal conditions), EPHX1 can hydrolyze most of the EETs
as they are formed; EPHX2 contributes minimally. However, when EET production rates are high (e.g.,
postischemic reperfusion), EPHX1 capacity is overwhelmed and EPHX2 then contributes significantly to
EET hydrolysis.
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